A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers
Latest Information Update: 11 Aug 2023
At a glance
- Drugs MSP008-22 (Primary)
- Indications COVID 2019 infections; Solid tumours
- Focus Adverse reactions
- Sponsors Godavari Biorefineries
Most Recent Events
- 10 Aug 2023 Status changed to recruiting, according to a Sathgen Therapeutics media release.
- 10 Aug 2023 According to a Sathgen Therapeutics media release, study has completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22.
- 14 Sep 2022 New trial record